US2016136154A1PendingUtilityA1

Extended release hydrocodone acetaminophen and related methods and uses thereof

33
Assignee: ABBVIE INCPriority: Feb 1, 2008Filed: Nov 19, 2015Published: May 19, 2016
Est. expiryFeb 1, 2028(~1.6 yrs left)· nominal 20-yr term from priority
A61P 43/00A61P 29/00A61P 25/04A61K 31/485A61K 31/165A61K 31/439A61K 31/167A61P 19/08A61P 19/02
33
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention generally provides a method of treatment and improvement of quality of life for patients adversely affected by various pain conditions. One preferred embodiment provides a method of treatment of acute pain, moderate to moderately severe pain, chronic pain, non-cancer pain, osteoarthritic pain, bunionectomy pain or lower back pain in a patient in need thereof, comprising providing at least one or two dosage form having about 15 mg of hydrocodone and its salt and about 500 mg of acetaminophen, once, twice or thrice daily. Preferably, the dosage form is about 30 mg of hydrocodone and about 1000 mg of acetaminophen taken twice daily. Alternatively, the dosage form is about 15 mg of hydrocodone and about 500 mg of acetaminophen taken twice daily.

Claims

exact text as granted — not AI-modified
1 . A method of treatment of acute pain, moderate to moderately severe pain, chronic pain, non-cancer pain, osteoarthritic pain, bunionectomy pain or lower back pain in a patient in need thereof comprises providing at least one or two dosage form comprising about 15 mg of hydrocodone and its salt and about 500 mg of acetaminophen, once, twice or thrice daily. 
     
     
         2 . The method according to  claim 1 , where the dosage form is about 30 mg of hydrocodone and about 1000 mg of acetaminophen taken twice daily. 
     
     
         3 . The method according to  claim 1 , wherein the dosage form is about 15 mg of hydrocodone and about 500 mg of acetaminophen taken twice daily. 
     
     
         4 . The method according to  claim 1 , wherein said dosage form may be taken by the patient with or without food. 
     
     
         5 . The method according to  claim 1 , wherein co-administration of about 240 ml of 40%, 20%, 4% and 0% ethanol on the single dosage form affects the mean maximum plasma concentration level Cmax by ≦25% for both hydrocodone and acetaminophen in the patient. 
     
     
         6 . The method according to  claim 1 , wherein Cmax and AUC of hydrocodone for a patient with mild to moderately impaired hepatic function is substantially similar to the normal patient and wherein Cmax and AUC of acetaminophen for a patient with mildly impaired hepatic function is substantially similar to the normal patient. 
     
     
         7 . The method according to  claim 1 , wherein no overall statistical differences in effectiveness is observed for the patient metabolizing hydrocodone when the patient is a poor or competent metabolizes of Cytochrome P450 2D6 polymorphism. 
     
     
         8 . A method of proving quality of life in a patient in need thereof, comprising administering to said patient a controlled release twice daily dosage form including acetaminophen and hydrocodone or a therapeutically effective salt thereof. 
     
     
         9 . A method of reducing loss of productivity in a patient having pain related condition, comprising administering to said patient a controlled release twice daily dosage form including acetaminophen and hydrocodone or a therapeutically effective salt thereof. 
     
     
         10 . The method of  claim 8 , wherein the dosage form comprises about 15 mg of hydrocodone or a therapeutically acceptable salt thereof and bout 500 mg of acetaminophen. 
     
     
         11 . The method of  claim 1 , wherein the dosage form comprises about 15 mg of hydrocodone or a therapeutically acceptable salt thereof and about 500 mg of acetaminophen. 
     
     
         12 . The method of  claim 1 , wherein the dosage form comprises about 30 mg of hydrocodone or a therapeutically acceptable salt thereof and about 1000 mg of acetaminophen.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.